MAPT and Alzheimer disease: T-Tau and P-Tau181 concentrations were significantly higher in the AD population than in the non-AD population (617 and 82 ng/L vs. 319 and 47 ng/L, p < 0.001, respectively) whereas CSF Aβ42 concentration and Aβ42/Aβ40 ratio were significantly lower in AD vs. non-AD patients (513 ng/L and 0.044 vs. 786 ng/L and 0.077, p < 0.001, respectively).